MeiraGTx and Hologen AI Form $430M Collaboration to Advance Parkinson’s Gene Therapy
MeiraGTx Enters Strategic Collaboration with Hologen AI for Parkinson's Gene Therapy
MeiraGTx will receive $200 million upfront payment from Hologen AI
Joint venture formed called Hologen Neuro AI Ltd, with $230 million additional committed capital from Hologen
Total potential value of deal is up to $430 million
Collaboration aims to expedite Phase 3 development of AAV-GAD gene therapy for Parkinson's disease
MeiraGTx retains 30% ownership in joint venture and will lead clinical development and manufacturing
Hologen to contribute AI technology to optimize development and manufacturing
Key Details:
AAV-GAD is MeiraGTx's gene therapy candidate for Parkinson's disease, which showed positive Phase 2 data in 2024
Hologen will apply its AI models to MeiraGTx's clinical data to improve trial design and success probability
Joint venture will also develop other CNS-targeted gene therapies
MeiraGTx to provide manufacturing for joint venture's products
Hologen gains minority stake in MeiraGTx's manufacturing subsidiary
Significance:
Creates first "neuro-AI" drug development company combining gene therapy and AI technologies
Provides significant funding and de-risking for MeiraGTx's lead Parkinson's program
Accelerates development timeline for AAV-GAD towards potential commercialization
Expands application of AI in CNS drug development and manufacturing optimization